Vir Biotechnology Inc. announced updated data from an ongoing Phase 1 trial of VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager, in patients with advanced metastatic castration-resistant prostate cancer (NCT05997615). The company reported that across 58 patients treated with VIR-5500 monotherapy, no dose-limiting toxicities were observed, grade 3 or higher treatment-related adverse events occurred in 12%, and cytokine release syndrome occurred in 50% of patients and was generally grade 1. In the highest dose cohorts (at least 3,000 µg/kg every three weeks; n=22) as of the January 9, 2026 data cut-off, PSA50 declines were reported in 82% of PSA-evaluable patients (14/17), PSA90 declines in 53% (9/17), and objective responses in 45% of RECIST-evaluable patients (5/11). The results will be presented in an oral session at the 2026 ASCO Genitourinary Cancers Symposium on February 26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260223892941) on February 23, 2026, and is solely responsible for the information contained therein.